Arginine methylation is a post-translational modification that plays pivotal roles in signal transduction and gene transcription during cell fate determination. We found protein methyltransferase 6 (PRMT6) to be frequently downregulated in hepatocellular carcinoma (HCC) and its expression to negatively correlate with aggressive cancer features in HCC patients. Silencing of PRMT6 promoted the tumor-initiating, metastasis, and therapy resistance potential of HCC cell lines and patient-derived organoids. Consistently, loss of PRMT6 expression aggravated liver tumorigenesis in a chemical-induced HCC PRMT6 knockout (PRMT6) mouse model. Integrated transcriptome and protein-protein interaction studies revealed an enrichment of genes implicated in RAS signaling and showed that PRMT6 interacted with CRAF on arginine 100, which decreased its RAS binding potential and altered its downstream MEK/ERK signaling. Our work describes a critical repressive function for PRMT6 in maintenance of HCC cells by regulating RAS binding and MEK/ERK signaling via methylation of CRAF on arginine 100.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.celrep.2018.09.053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ID3 promotes erythroid differentiation and is repressed by a TAL1/PRMT6 complex.
J Biol Chem
December 2024
University of Stuttgart, Institute of Biomedical Genetics, Department of Eukaryotic Genetics, Allmandring 31, 70569 Stuttgart, Germany. Electronic address:
Erythropoiesis is controlled by transcription factors that recruit epigenetic cofactors to establish and maintain erythrocyte-specific gene expression patterns while repressing alternative lineage commitment. The transcription factor TAL1 is critical for establishing erythroid gene expression. It acts as an activator or repressor of genes, depending on associated epigenetic cofactors.
View Article and Find Full Text PDFTargeting PRMT1 reduces cancer persistence and tumor relapse in EGFR- and KRAS-mutant lung cancer.
Cancer Res Commun
December 2024
University of California, San Francisco, San Francisco, CA, United States.
Incomplete killing of cancer cells undermines oncogene-targeting therapies and drives disease relapse. Eliminating cancer cells that persist during treatment is crucial for improving treatment outcomes. Here, we discovered that a specific isoform of type I protein arginine methyltransferases (PRMTs), namely PRMT1, enables lung cancer cells with EGFR or KRASG12C driver mutations and high STAT1 activity to persist through targeted drug treatments.
View Article and Find Full Text PDFDNA methylation biomarkers and myopia: a multi-omics study integrating GWAS, mQTL and eQTL data.
Clin Epigenetics
November 2024
School of Public Health, The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.
Background: This study aimed to identify DNA methylation biomarkers associated with myopia using summary-data-based Mendelian randomization (SMR).
Methods: A systematic search of the PubMed, Web of Science, Cochrane Library, and Embase databases was conducted up to March 27, 2024. SMR analyses were performed to integrate genome-wide association study (GWAS) with methylation quantitative trait loci (mQTL) and expression quantitative trait loci (eQTL) studies.
Uncovering cell-type-specific immunomodulatory variants and molecular phenotypes in COVID-19 using structurally resolved protein networks.
Cell Rep
November 2024
Center for Systems Immunology, Departments of Immunology and Computational & Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address:
Article Synopsis
- Researchers suggest a new network-based method to identify immunomodulatory genetic variants linked to COVID-19 by analyzing protein interaction networks.
- They discovered that variants affecting specific protein interactions can significantly impact immune response, even if they don't reach usual statistical significance in genome-wide studies.
- Their findings highlight the importance of myeloid and T cell subsets in the immune response and point out a specific variant that disrupts a key protein interaction related to interferon signaling.
Protein arginine methyltransferase-6 regulates heterogeneous nuclear ribonucleoprotein-F expression and is a potential target for the treatment of neuropathic pain.
Neural Regen Res
September 2025
Department of Anesthesiology, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Article Synopsis
- * Research using various pain models showed that PRMT6 expression decreases after nerve injuries, and mice lacking PRMT6 (Prmt6-/-) exhibited heightened pain sensitivity.
- * PRMT6 may contribute to neuropathic pain by influencing the expression of heterogeneous nuclear ribonucleoprotein-F, with specific amino acids being crucial for this regulatory function.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!